The future targeted therapies and ADCs in metastatic endometrial cancer
Автор: VJOncology
Загружено: 2026-01-13
Просмотров: 10
Описание:
Ka Yu Tse, MBBS, The University of Hong Kong, Hong Kong, China, comments on the potential role of PARP inhibitors with immunotherapy for patients with advanced endometrial cancer. While overall hazard ratios are modest, certain subgroups such as those with homologous recombination repair (HRR) gene mutations or P53 abnormal expression may derive greater benefit. HER2-targeting therapies and antibody-drug conjugates (ADCs) may offer promising options for patients with specific molecular characteristics, such as HER2 mutations or amplifications. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
